Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo

GLIA

Volumn 63, Issue 1, 2015, Pages 163-176

  Bernal Chico, Ana ^a,b   Canedo, Manuel ^a,b   Manterola, Andrea ^a   Victoria Sánchez Gómez, María ^a,b,c   Pérez Samartín, Alberto ^a,b,c   Rodríguez Puertas, Rafael ^a   Matute, Carlos ^a,b,c   Mato, Susana ^a,b,c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

2 AG; AMPA receptors; CB1< inf> receptors; Multiple sclerosis; Myelin

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ACYLGLYCEROL LIPASE; AMIDASE; BENZAMIDE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; FATTY-ACID AMIDE HYDROLASE; PIPERIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DEMYELINATING DISEASES; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; SPRAGUE DAWLEY RAT;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; BENZODIOXOLES; CANNABINOID RECEPTOR MODULATORS; CARBAMATES; DEMYELINATING DISEASES; MONOACYLGLYCEROL LIPASES; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PIPERIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 84911403377     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22742     Document Type: Article

References (58)

1. Alberdi E, Sánchez-Gómez MV, Marino A, Matute C. 2002. Ca(2+) influx through AMPA or kainate receptors alone is sufficient to initiate excitotoxicity in cultured oligodendrocytes. Neurobiol Dis 9:234-243.
2. Azami Tameh A, Clarner T, Beyer C, Atlasi MA, Hassanzadeh G, Naderian H. 2013. Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain. Ann Anat 195:415-423.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. 2000. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87.
4. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL. 2008. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118:1532-1543.
5. Blankman JL, Simon GM, Cravatt BF. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14:1347-1356.
6. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. 2011. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479-486.
7. Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang YP, Teng Z, Chen C. 2012. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep 2:1329-1339.
8. Crawford DK, Mangiardi M, Xia X, López-Valdés HE, Tiwari-Woodruff SK. 2009. Functional recovery of callosal axons following demyelination: A critical window. Neuroscience 164:1407-1421.
9. Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. 2008. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 193:120-129.
10. Dinh TP, Freund TF, Piomelli D. 2002. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121:149-158.
11. Dutta R, Chomyk AM, Chang A, Ribaudo MV, Deckard SA, Doud MK, Edberg DD, Bai B, Li M, Baranzini SE, Fox RJ, Staugaitis SM, Macklin WB, Trapp BD. 2013. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 73:637-645.
12. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49:67-79.
13. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. 2000. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 20:9235-9241.
14. Franklin KB, Paxinos G. 1997. The mouse brain in stereotaxic coordinates. San Diego, USA: Elsevier Academic Press.
15. Gomez O, Arevalo-Martin A, Garcia-Ovejero D, Ortega-Gutierrez S, Cisneros JA, Almazan G, Sánchez-Rodriguez MA, Molina-Holgado F, Molina-Holgado E. 2010. The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 58:1913-1927.
16. Gomez O, Sanchez-Rodriguez A, Le M, Sanchez-Caro C, Molina-Holgado F, Molina-Holgado E. 2011. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol 163:1520-1532.
17. Hardin-Pouzet H, Krakowski M, Bourbonnière L, Didier-Bazes M, Tran E, Owens T. 1997. Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20:79-85.
18. Irvine KA, Blakemore WF. 2006. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 175:69-76.
19. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D. 2005. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134:261-268.
20. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P. 2010. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13:180-189.
21. Kreutz S, Koch M, Ghadban C, Korf HW, Dehghani F. 2007. Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol 203:246-257.
22. Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M. 2009. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453:120-125.
23. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF. 2009. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
24. Lozovaya N, Min R, Tsintsadze V, Burnashev N. 2009. Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects. Cell Calcium 46:154-162.
25. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. 2007. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492-497.
26. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, Li W, Xu C, Möller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N. 2010. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13:951-957.
27. Mato S, Alberdi E, Ledent C, Watanabe M, Matute C. 2009. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes. Glia 57:295-306.
28. Mato S, Sánchez-Gómez MV, Bernal-Chico A, Matute C. 2013. Cytosolic zinc accumulation contributes to excitotoxic oligodendroglial death. Glia 61:750-764.
29. Matute C, Sánchez-Gómez MV, Martínez-Millán L, Miledi R. 1997. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 94:8830-8835.
30. Matute C, Torre I, Pérez-Cerdá F, Pérez-Samartín A, Alberdi E, Etxebarria E, Arranz AM, Ravid R, Rodríguez-Antigüedad A, Sánchez-Gómez M, Domercq M. 2007. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27:9525-9533.
31. McCarthy KD, de Vellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.
32. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. 1998. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 4:291-297.
33. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, Muntoni AL, Lutz B, Gessa GL, Marsicano G, Di Marzo V, Pistis M. 2006. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 24:15-27.
34. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, Yin X, Trapp BD, McRory JE, Rehak R, Zamponi GW, Wang W, Stys PK. 2006. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439:988-992.
35. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22:9742-9753.
36. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF. 2011. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334:809-813.
37. Ohgoh M, Hanada T, Smith T, Hashimoto T, Ueno M, Yamanishi Y, Watanabe M, Nishizawa Y. 2002. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J Neuroimmunol 125:170-178.
38. Ohno-Shosaku T, Hashimotodani Y, Ano M, Takeda S, Tsubokawa H, Kano M. 2007. Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons. J Physiol 584:407-418.
39. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, Benito C, Romero J, Silva A, Guzmán M, Nataf S, Galve-Roperh I. 2008. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283:13320-13329.
40. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. 2005. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25:477-484.
41. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531.
42. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM, Schwartz JW, Nomura DK, Samad TA. 2012. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep 1:617-623.
43. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70.
44. Plaut GS. 1987. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J R Soc Med 80:91-93.
45. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126:2191-2202.
46. Ribeiro R, Yu F, Wen J, Vana A, Zhang Y. 2013. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis. Neuroscience 254:427-442.
47. Sarchielli P, Greco L, Floridi A, Gallai V. 2003. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch Neurol 60:1082-1088.
48. Sánchez-Gómez MV, Alberdi E, Ibarretxe G, Torre I, Matute C. 2003. Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 23:9519-9528.
49. Sánchez-Gómez MV, Alberdi E, Pérez-Navarro E, Alberch J, Matute C. 2011. Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors. J Neurosci 31:2996-3006.
50. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu Q, Lichtman AH, Cravatt BF. 2010. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119.
51. Sciolino NR, Zhou W, Hohmann AG. 2011. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226-234.
52. Skripuletz T, Gudi V, Hackstette D, Stangel M. 2011. De- and remyelination in the CNS white and grey matter induced by cuprizone: The old, the new, and the unexpected. Histol Histopathol 26:1585-1597.
53. Smith T, Groom A, Zhu B, Turski L. 2000. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62-66.
54. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. 2005. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016-1025.
55. Stover JF, Lowitzsch K, Kempski OS. 1997. Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett 238:25-28.
56. Vallejo-Illarramendi A, Domercq M, Pérez-Cerdá F, Ravid R, Matute C. 2006. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21:154-164.
57. Wallström E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. 1996. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137:89-96.
58. Werner P, Pitt D, Raine CS. 2001. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169-180.